Harrow Re-launches VERKAZIA for Vernal Keratoconjunctivitis

Key Highlights

• Harrow re-launched VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for vernal keratoconjunctivitis (VKC).
• VERKAZIA is indicated for all forms of VKC, a serious allergic eye disease primarily affecting children.
• It is a calcineurin inhibitor immunomodulator targeting inflammatory mechanisms of VKC.
• The therapy may reduce the need for steroid rescue, avoiding risks like glaucoma or cataract formation.
• The re-launch includes a commercial strategy focused on physician education, patient access, and affordability.
• VKC is a chronic, potentially sight-threatening condition with limited historical treatment options.
• Prior to VERKAZIA, no FDA-approved steroid-sparing therapy existed for VKC.